CollPlant awarded CE Mark for Tendinopathy treatment

Yehiel Tal Photo: PR

Earlier this year, the Israeli tissue repair company also received a CE Mark for VergenixFG for the treatment of chronic and surgical wounds.

Israeli regenerative medicine company CollPlant Holdings Ltd. (TASE: CLPT) has been awarded the EU CE Mark for VergenixSTR, a soft tissue repair matrix for the treatment of tendinopathy. Sales in Europe are expected to commence in the coming months. The Ness Ziona based company specializes in regenerative medicine by utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products.

CollPlant CEO Yehiel Tal said, “The CE Mark for VergenixSTR denotes an additional and key milestone achieved by CollPlant. In the past few months, we have shown that treatment with our product provides for substantially superior results when compared to published steroid treatment results, the current standard of care for tendinopathy. We are presently in dialogue with potential distributers for product marketing in Europe and expect initial sales within the coming months. Of note, this is the second CE Mark the company received this year, with the first granted at the beginning of the year, to its VergenixFG product, indicated for the treatment of chronic and surgical wounds. These accomplishments advance the company’s strategic plan to position plant-bad human collagen technology, and its medical byproducts, as the gold standard in regenerative medicine."

Published by Globes [online], Israel business news - - on October 19, 2016

© Copyright of Globes Publisher Itonut (1983) Ltd. 2016 .

Yehiel Tal Photo: PR
Yehiel Tal Photo: PR
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018